🔎 Trials Near Me

Utama › Leukemia Limfositik Kronik › Alabama

Kajian klinikal Leukemia Limfositik Kronik di Alabama

7 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi di Alabama.

Bandar di Alabama

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • University of Alabama at Birmingham Cancer Center, Birmingham
Mengambil pesertaFasa 3
Umur 65 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07321652

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • University of Alabama At Birmingham Hospital, Birmingham
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • University of Alabama At Birmingham Hospital, Birmingham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • USA Mitchell Cancer Institute ( Site 0014), Mobile
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06136559

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Mitchell Cancer Institute, Mobile
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07218341

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922

HPC Offered for PRESERVE Expansion

  • University of Alabama, Birmingham, Birmingham
Mengambil pesertaKajian pemerhatian
Umur 12 hingga 80 · Semua jantina · Dikemas kini 28 Ogo 2025 · NCT07145411

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.